Bioregenx (BRGX) Notes Payables (2022 - 2023)
Bioregenx's (BRGX) quarterly Notes Payables came in at $25370.0 in Q4 2023, down 38.08% year-on-year from $40970.0 in Q4 2022, and up 76.3% quarter-over-quarter from $14390.0 in Q3 2023.
Bioregenx (BRGX) Notes Payables (2022 - 2023) Analysis & Trends
Bioregenx's Notes Payables history runs 2 years deep, the most recent figure standing at $25370.0 for Q4 2023.
- On a quarterly basis, Notes Payables fell 38.08% year-over-year to $25370.0 in Q4 2023; TTM through Dec 2023 was $25370.0, a 38.08% decrease from a year earlier, with the FY2023 full-year figure at $25370.0, down 38.08% from the prior year.
- Notes Payables advanced to $25370.0 in Q4 2023 per BRGX's latest filing, from $14390.0 in the prior quarter.
- Across five years, Notes Payables topped out at $40970.0 in Q4 2022 and bottomed at $12590.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 31.81 Bn | 24.49 Bn | 662.02 Mn |
| 2 | BrightSpring Health Services | 14.76 Bn | 13.86 Bn | 482.22 Mn |
| 3 | Healthequity | 8.36 Bn | 8.10 Bn | 256.31 Mn |
| 4 | Hinge Health | 5.91 Bn | 5.60 Bn | 154.23 Mn |
| 5 | 10x Genomics | 5.89 Bn | 5.35 Bn | 106.18 Mn |
| 6 | MiniMed | 4.45 Bn | 4.16 Bn | 480.00 Mn |
| 7 | Waystar Holding | 4.41 Bn | 4.35 Bn | 216.84 Mn |
| 8 | Doximity | 3.93 Bn | 3.18 Bn | 125.97 Mn |
| 9 | Privia Health | 3.10 Bn | 2.68 Bn | - |
| 10 | Bioregenx | 9.69 Mn | 9.65 Mn | 348,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 25,370.00 |
| Sep 30, 2023 | 14,390.00 |
| Jun 30, 2023 | 12,590.00 |
| Mar 31, 2023 | 12,590.00 |
| Dec 31, 2022 | 40,970.00 |